• 原料直供
• 试剂商城
• 直接询价

分类

• {SNA} Abbott,
• {SNA} Abbott, Anticonvulsants, Antitumor Agents, Approved Therapeutics/Drug Candidates, Bioactive Small Molecule Alphabetical Index, Bioactive Small Molecules for Epigenetic Research, Enzyme Inhibitors, Histone Deacetylase Inhibitors, Neurobiology, Neuroscience, Pharmacologicals,
• {SNA} An
• {SNA} Abbott, Anticonvulsants, Antitumor Agents, Approved Therapeutics/Drug Candidates, Bioactive Small Molecules, Bioactive Small Molecules for Epigenetic Research,
• {SNA} Analytical Standards, Chromatography, EP Standards, EP Standards S - T, Pharmaceutical Standards, Pharmacopeia Standards, 分析/色谱
• {SNA} Abbott

产品应用

• Antiepileptic; increases levels of GABA in the brain.

相关文献及参考

• Chang, Z.L., et al.: Anal. Profiles Drug Subs., 8, 529 (1979),
• Nau, H., et al.: Pharmacol. Toxicol., 69, 310 (1991),
• Hauke, J., et al., Survival Motor Neuron Gene 2 Silencing By DNA Methylation Correlates With Spinal Muscular Atrophy Disease Severity And Can Be Bypassed By Histone Deacetylase Inhibition. Hum. Mol. Genet. 18 , 304-17, (2009) 摘要
• Baltus, G.A., et al., A Positive Regulatory Role For The MSin3A-HDAC Complex In Pluripotency Through Nanog And Sox2. J. Thorac. Cardiovasc. Surg. 284 , 6998-7006, (2009) 摘要
• Taubøll, E., et al., Effects Of Levetiracetam And Valproate On Reproductive Endocrine Function Studied In Human Ovarian Follicular Cells. Epilepsia 50 , 1868-74, (2009) 摘要
• Kyriss, M.N., et al., Novel Functional Residues In The Core Domain Of Histone H2B Regulate Yeast Gene Expression And Silencing And Affect The Response To DNA Damage. Mol. Cell. Biol. 30 , 3503-18, (2010) 摘要
• Grimes, C.A. and Jope, R.S., Cholinergic stimulation of early growth response-1 DNA binding activity requires protein kinase C and mitogen-activated protein kinase kinase activation and is inhibited by sodium valproate in SH-SY5Y cells. J. Neurochem. 73 , 1384-1392, (1999)
• Della Paschoa, O.E., et al., Modelling of the pharmacodynamic interaction between phenytoin and sodium valproate. Br. J. Pharmacol. 125 , 1610-1616, (1998) 摘要
• Merck 14 ,9913

安全信息

GHS Symbol

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Oral
SPECIES OBSERVED        : Human - woman
DOSE/DURATION           : 500 mg/kg
TOXIC EFFECTS :
   Behavioral - sleep
   Behavioral - muscle weakness
REFERENCE :
   PGMJAO Postgraduate Medical Journal.  (Blackwell Scientific Pub. Ltd., POB
   88, Oxford, UK) V.1-    1925-  Volume(issu

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Oral
SPECIES OBSERVED        : Human - man
DOSE/DURATION           : 214 mg/kg/30D-I
TOXIC EFFECTS :
   Skin and Appendages - dermatitis, allergic (after systemic exposure)
REFERENCE :
   IJMDAI Israel Journal of Medical Sciences.  (POB 1435, Jerusalem 91013,
   Israel)  V.1-    1965-  Volume(issue)/page/year: 30,283,1994

TYPE OF TEST            : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE       : Oral
SPECIES OBSERVED        : Rodent - rabbit
DOSE/DURATION           : 1468 mg/kg
TOXIC EFFECTS :
   Details of toxic effects not reported other than lethal dose value
REFERENCE :
   KSRNAM Kiso to Rinsho.  Clinical Report.  (Yubunsha Co., Ltd., 1-5, Kanda
   Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan)  V.1-    1960-
   Volume(issue)/page/year: 5,41,1971

TYPE OF TEST            : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE       : Oral
SPECIES OBSERVED        : Mammal - dog

TYPE OF TEST            : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE       : Intraperitoneal
SPECIES OBSERVED        : Mammal - dog
DOSE/DURATION           : 700 mg/kg
TOXIC EFFECTS :
   Behavioral - somnolence (general depressed activity)
   Behavioral - tremor
   Behavioral - ataxia
REFERENCE :
   PBPSDY Pharmacological and Biochemical Properties of Drug Substances.
   (American Pharmaceutical Assoc., 2215 Constitution Ave., NW, Washington, DC
   20037)  V.1-    1977-  Volume(issue)/page/year: 2,58,1979

TYPE OF TEST            : Sister chromatid exchange
TEST SYSTEM             : Human Lymphocyte
DOSE/DURATION           : 5 mg/L
REFERENCE :
   MUREAV Mutation Research.  (Elsevier Science Pub. B.V., POB 211, 1000 AE
   Amsterdam, Netherlands) V.1-    1964-  Volume(issue)/page/year: 243,63,1990

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Oral
SPECIES OBSERVED        : Human - woman
DOSE                    : 1620 mg/kg
SEX/DURATION            : female 1-39 week(s) after conception
TOXIC EFFECTS :
   Reproductive - Specific Developmental Abnormalities - hepatobiliary system
REFERENCE :
   LANCAO Lancet.  (7 Adam St., London WC2N 6AD, UK)  V.1-    1823-
   Volume(issue)/page/year: 2,1518,1987

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Oral
SPECIES OBSERVED        : Rodent - rabbit
DOSE                    : 5200 mg/kg
SEX/DURATION            : female 6-18 day(s) after conception
TOXIC EFFECTS :
   Reproductive - Fertility - post-implantation mortality (e.g. dead and/or
   resorbed implants per total number of implants)
   Reproductive - Effects on Embryo or Fetus - fetal death
   Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured
   before birth)
REFERENCE :
   ChaEB# Personal Communication from E.B. Chappel, Abbott Labs., N. Chicago,
   IL, Jan. 19, 1978  Volume(issue)/page/year: 19JAN1978

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Oral
SPECIES OBSERVED        : Rodent - mouse
DO

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Oral
SPECIES OBSERVED        : Primate - monkey
DOSE                    : 3 gm/kg
SEX/DURATION            : female 21-50 day(s) after conception
TOXIC EFFECTS :
   Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death,
   e.g., stunted fetus)
   Reproductive - Specific Developmental Abnormalities - craniofacial
   (including nose and tongue)
REFERENCE :
   TJADAB Teratology, The International Journal of Abnormal Development. (Alan
   R. Liss, Inc., 41 E. 11th St., New York, NY 10003)  V.1-    1968-
   Volume(issue)/page/year: 38,329,1988

其他信息

• MSDS 信息:2-Propylpentanoic acid sodium salt(1069-66-5).msds
• Sigma Aldrich:1069-66-5(sigmaaldrich)
• MOL 文件:1069-66-5.mol
• 外观:白色结晶或结晶性粉末
• 用途一:1069-66-5（丙戊酸钠）是一种不含氮的广谱抗癫痫药，用于治疗和预防各种类型癫痫，对失神性小发作、癫痫性行动失常等疗效更好。
• Acros Organics:丙戊酸钠 2-Propylpentanoic acid, sodium salt, 98%(1069-66-5)
• 丙戊酸钠价格(试剂级):更新日期 产品编号 产品名称 包装 价格 2010/06/21 271830050 丙戊酸钠 2-Propylpentanoic acid, sodium salt 98% 5 GR 260元 2010/06/21 271830250 丙戊酸钠 2-Propylpentanoic acid, sodium salt 98% 25 GR 690元
• 质量标准:碱　度 PH　值应为7.5-9.0 干燥失重 ≤3.0% 重　金　属 不得过百万分之二十 甲醇残留量 ≤0.01% 甲苯残留量 ≤0.089% 含量测定 按干燥品计算，含C18H15NO3不得少于99.0%
• 上游原料:乙酰乙酸甲酯